Adoptive Cell Therapy for T-Cell Malignancies

T-cell malignancies are often aggressive and associated with poor prognoses. Adoptive cell therapy has recently shown promise as a new line of therapy for patients with hematological malignancies. However, there are currently challenges in applying adoptive cell therapy to T-cell malignancies. Various approaches have been examined in preclinical and clinical studies to overcome these obstacles. This review aims to provide an overview of the recent progress on adoptive cell therapy for T-cell malignancies. The benefits and drawbacks of different types of adoptive cell therapy are discussed. The potential advantages and current applications of innate immune cell-based adoptive cell therapy for T cell malignancies are emphasized.

Automated summary

T-cell malignancies are aggressive and have poor prognoses, but adoptive cell therapy has shown promise as a new treatment option. Overcoming challenges, such as difficulties in applying this therapy to T-cell malignancies, is a focus of research. This review provides an overview of recent progress in adoptive cell therapy for T-cell malignancies, discussing the benefits and drawbacks of different therapy types and emphasizing the potential advantages and current applications of innate immune cell-based approaches.